Immunogenicity, reactogenicity, and safety to assess booster vaccinations with BNT162b2 or double-dose mRNA-1273 in adults ≥75 years (EU-COVAT-1-AGED)-final report.
Stemler J, Yeghiazaryan L, Stephan C, Greve-Isdahl Mohn K, Cox RJ, Carcas-Sansuan AJ, Romero Rodriguez E, Moltó J, Vergara Mitxeltorena I, Pink I, Welte T, Zablockienė B, Akova M, Bethe U, Grimm S, Salmanton-García J, Jakobs J, Tischmann L, Zarrouk M, Cüppers A, Biehl LM, Grothe J, Mellinghoff SC, Nacov JA, Neuhann JM, Sprute R, Frías-Iniesta J, Negi R, Gaillard C, Saini G, León AG, Mallon PWG, Lammens C, Hotterbeekx A, Loens K, Malhotra-Kumar S, Goossens H, Kumar-Singh S, König F, Posch M, Koehler P, Cornely OA; EU-COVAT-1 AGED study group on behalf of the VACCELERATE Consortium.
Stemler J, et al. Among authors: hotterbeekx a.
Int J Infect Dis. 2026 Apr;165:108466. doi: 10.1016/j.ijid.2026.108466. Epub 2026 Feb 6.
Int J Infect Dis. 2026.
PMID: 41655623
Free article.
Clinical Trial.